

Advancing PCI outcome in diabetics with the innovative Cre8[™] EVO DES

PCI with Cre8[™] EVO in a T2DM patient

Daniel Aradi, MD PhD FESC Head of Interventional Cardiology Unit Heart Center Balatonfüred HUNGARY



TCTAP 2022

Disclosure statement

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.



Lecture fees

Company

Alvimedica Bayer Boehringer Ingelheim MSD Pharma Organon Pfizer





HISTORY

- Gender: Male
- Age: 68 ys
- Height: 174 cm. Weight: 76 kg. BMI: 25.1 kg/m².
- CV risk factors:
 - T2DM (7 ys)
 - Hipertension (15 ys)
- Previous MI: NO
- Previous PCI/CABG: NO
- Rx: aspirin 1x100 mg, perindopril 1x5 mg, pantoprazole 1x20 mg, metformin 2x1000 mg.





CURRENT PRESENTATION (August 2021): NSTEMI

- Typical chest pain at rest
- ECG: Sinus rhythm, HR: 53/min, II-III-aVF: negative T waves
- Lab:


hsTrop:	131 ng/ml.
Hgb:	13.9 g/dl
eGFR:	81 ml/min/1.73m2


- Echo:
 - EF: 55%, inferior hypokinesis





CORONARY ANGIOGRAPHY







LAD: long, calcified, diffusely diseased lesion, CTO?




CORONARY ANGIOGRAPHY



Syntax score: 30.

?Alvimedica

TCTAP 2022






Guidewire passage, aspiration thrombectomy

CRE8 EVO 3.0 x 33 mm





RCA PCI






CRE8 EVO 3.5 x 46 mm





RCA PCI



High pressure NC post-dilations 3.5x20 mm, 22 atm




Final result of the RCA PCI with 2 CRE8 EVO





LAD attempt



Guidewire crosses LAD occlusion, but 1.0 x 10 mm ballon fails to pass







CLINICAL COURSE POST PCI


- No complication, patient became symptom-free
- CK, CKMB: normal, peak hsTroponin: 580 ng/ml.

- MRI: EF: 53%, subendocardial late enhancement in infero-basal and mid segments, LAD territory viable
- Due to effort angina:
- Decision to re-attempt LAD CTO PCI, 4 months after the first PCI



RCA PCI results at 4 months









Good result in CRE8 EVO 3.5 x 46 mm and CRE8 EVO 3.0 x 33 mm





















CRE8 EVO 2.75 x 20 mm









After proximal LAD stenting with 2 CRE8 EVO









CRE8 EVO 2.0 x 26 mm

Final result





Clinical follow-up

- 7 months after the initial PCI, no recurrent clinical events / hospitalisation
- Angina-free
- DAPT: planned until Aug 2022.



